The global dermatology prescription market is expected to continue growing at a rapid pace.
In our Therapeutic Dermatology business we provide dermatologists and other healthcare professionals with prescription treatments that offer patients relief from the burden of moderate to severe skin diseases. We have a wide-ranging portfolio and our innovation is focused on developing new therapies in more disease areas with unmet medical needs.
One of our key priorities is to advance the development of the investigational therapy nemolizumab in patients with atopic dermatitis and prurigo nodularis for which we are completing Phase 3 clinical studies.
About us
